Cargando…

Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine

Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrari, Ludovica, Compagno, Mirko, Campogiani, Laura, Teti, Elisabetta, Mulas, Tiziana, Checchi, Davide, Alessio, Grazia, Caldara, Federica, Coppola, Luigi, De Simone, Giuseppe, Ceccarelli, Laura, Spalliera, Ilaria, Vitale, Pietro, Grelli, Sandro, Andreoni, Massimo, Sarmati, Loredana, Iannetta, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414957/ https://www.ncbi.nlm.nih.gov/pubmed/36016128 http://dx.doi.org/10.3390/vaccines10081238

Ejemplares similares

1970. SARS-CoV-2 T-cell specific responses in allogeneic hematopoietic stem cell transplant recipients after second and third dose of BNT162b2 mRNA vaccine
por: Marco, Iannetta, et al.
Publicado: (2022)

Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
por: Campogiani, Laura, et al.
Publicado: (2023)

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
por: Iannetta, Marco, et al.
Publicado: (2021)

280. Monoclonal Antibodies Against SARS-CoV-2 in Fragile Outpatients: Clinical and Laboratory Risk Factors and Protective Role of Vaccination
por: Cavasio, Rosario Alessandro, et al.
Publicado: (2022)

Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience
por: Campogiani, Laura, et al.
Publicado: (2023)

In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production
por: Imeneo, Alessandra, et al.
Publicado: (2022)

1438. Latent tuberculosis infection (LTBI) in hematopoietic stem cell transplantation (HSCT) recipients: a retrospective Italian cohort study in Tor Vergata University Hospital, Rome.
por: Compagno, Mirko, et al.
Publicado: (2022)

766. Migration Flows and Increase of Extrapulmonary Tuberculosis in a Low Prevalence Setting: A Retrospective Analysis in Two Italian Centers
por: Compagno, Mirko, et al.
Publicado: (2018)

Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study
por: Iannetta, Marco, et al.
Publicado: (2021)

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

1139. Oral Antivirals Against SARS-CoV-2: a New Valid Strategy Against COVID-19
por: Braccialarghe, Neva, et al.
Publicado: (2022)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
por: Iannetta, Marco, et al.
Publicado: (2022)

Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome
por: Compagno, Mirko, et al.
Publicado: (2022)

Tuberculosis-Related Hospitalizations in a Low-Incidence Country: A Retrospective Analysis in Two Italian Infectious Diseases Wards
por: Campogiani, Laura, et al.
Publicado: (2019)

Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production
por: Alessio, Grazia, et al.
Publicado: (2022)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients
por: Di Lorenzo, Andrea, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

2169. A 4-Year Analysis of Antimicrobial Susceptibility to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: How Drug Availability Affects Resistance Rate
por: Imeneo, Alessandra, et al.
Publicado: (2023)

Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization
por: Iannetta, Marco, et al.
Publicado: (2022)

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir
por: Campogiani, Laura, et al.
Publicado: (2019)

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2023)

The Impact of Viral and Bacterial Co-Infections and Home Antibiotic Treatment in SARS-CoV-2 Hospitalized Patients at the Policlinico Tor Vergata Hospital, Rome, Italy
por: Di Lorenzo, Andrea, et al.
Publicado: (2023)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination
por: Koike, Ryousuke, et al.
Publicado: (2022)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
por: Malipiero, Giacomo, et al.
Publicado: (2022)

Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model
por: Matsumoto, Naomi, et al.
Publicado: (2023)

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease †
por: Alessio, Loredana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gtomdlfjcirsporktjue8uj9t1